A dual GIP/GLP-1 receptor co-agonist (Mounjaro/Zepbound) with the strongest weight-loss data of any approved agent to date.
Activates two incretin receptors at once: the GLP-1 arm boosts insulin, suppresses glucagon, slows gastric emptying and increases satiety; the GIP arm adds effects on insulin sensitivity and adipose fat handling, acting synergistically.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
No reviews yet. If you've used Tirzepatide, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.